Educational Campaign Will Help Empower Women to
Have Open and Candid Conversations about Reproductive Health and
Contraceptive Options
Whitney Cummings Shares Her Experience
Switching to ANNOVERA® (segesterone acetate and ethinyl estradiol
vaginal system)
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s
healthcare company, announced the launch of Just Say Vagina to
encourage women to speak clearly and directly about their
reproductive health. Comedian Whitney Cummings will discuss her
journey from serial apologizer to an unapologetic role model who no
longer uses euphemisms or apologizes in the way she speaks about
birth control.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201215005653/en/
(Photo Credit: Whitney Cummings)
“I used to apologize a lot. But now I’m encouraging all women to
channel their inner superpower and ditch the V word,” explained
Whitney Cummings. “I’ve learned that when you use euphemisms, it
makes it harder to say what you mean and to ask for what you need.
It’s not cha cha. It’s not hoo hah. Just say it. Vagina.”
Whitney Cummings has used hormonal birth control for nearly two
decades and recently decided it was time for a switch. She spoke to
her doctor and they decided that ANNOVERA® (segesterone acetate and
ethinyl estradiol vaginal system) was the right choice for her.
ANNOVERA is the first annual, comfortable, and procedure-free birth
control. It's a soft and squishy ring that a woman inserts into her
vagina. When squeezed, the ring is about the same size as a tampon.
ANNOVERA is inserted for 21 days and then removed for seven days
each cycle, for one year (13 cycles).
“I always ask my patients ‘how’s your vagina?’” explained Mary
Jane Minkin, MD, Yale University School of Medicine. “I want my
patients to feel comfortable speaking directly to me about their
needs. Once we are all comfortable, I can better support my
patient’s wellness and I can help her determine what will work best
for her in a more productive and clear way.”
There are consequences when a woman is not comfortable being
direct about her contraceptive preferences. In the United States,
the unintended pregnancy rate is 45 percent and 41 percent of
unintended pregnancies are due to inconsistent use of
contraceptives.1,2,3 In addition, women are dissatisfied when it
comes to birth control, with 47 percent of female birth control
users discontinuing use of a contraceptive method due to a variety
of factors, such as side effects, effectiveness, sexual pleasure,
partner preference, and cost.4
In addition, an online analysis of more than 724 million social
conversations confirmed that women unnecessarily apologize more
than men when it comes to reproductive health. In fact, women
apologize 30 times more than men when discussing birth control.
"It’s time for open, honest, and unapologetic conversations
about birth control. We are proud to partner with Whitney Cummings
to usher in the next generation of empowered women," said Dawn
Halkuff, Chief Commercial Officer of TherapeuticsMD. "It is
important for women to be educated about their bodies and the
contraceptive options available to them. We hope that Whitney
inspires other women to be more comfortable and candid when
discussing their reproductive health needs."
You can learn more at www.JustSayVagina.com, where you will find
a doctor discussion guide.
About ANNOVERA
ANNOVERA is the first and only FDA-approved long-lasting,
reversible contraceptive for women of reproductive age that is
patient-controlled and procedure-free. ANNOVERA was developed by
the global non-profit research organization, Population Council and
has been licensed to TherapeuticsMD for the U.S. market.
IMPORTANT RISK INFORMATION
- Do not use ANNOVERA (segesterone acetate and ethinyl
estradiol vaginal system) if you smoke cigarettes and are over 35
years old. Smoking increases your risk of serious heart and blood
vessel (cardiovascular) side effects from hormonal birth control
methods, including death from heart attack, blood clots, or stroke.
This risk increases with age and the number of cigarettes you
smoke.
- ANNOVERA does not protect against HIV infection (AIDS) and
other sexually transmitted infections (STIs).
DO NOT USE ANNOVERA IF YOU
- have or have had a blood clot in your arms, legs, lungs, or
eyes.
- have had a stroke.
- have reduced blood flow to your brain (cerebrovascular
disease).
- have reduced blood flow or blockage in 1 or more of the
arteries that supply blood to your heart (coronary artery
disease).
- have had a heart attack.
- have heart rhythm or heart valve problems that increase your
risk of having blood clots, such as an infection of the inner
lining of the heart and heart valves or a type of irregular
heartbeat called atrial fibrillation.
- have a problem with your blood that makes it clot more than
normal.
- have high blood pressure that is not controlled with medicine
or have high blood pressure with blood vessel damage.
- have diabetes and are over 35 years old; have diabetes with
high blood pressure or problems with your kidneys, blood vessels,
eyes, or nerves; or have had diabetes for longer than 20
years.
- have headaches with changes in vision, numbness or weakness,
have migraine headaches with aura, or are over age 35 years old and
have any type of migraine headaches.
- have liver disease or liver tumors.
- have or have had breast cancer or any cancer that is sensitive
to the female hormones estrogen or progesterone.
- have unexplained vaginal bleeding.
- are allergic to segesterone acetate, ethinyl estradiol, or any
of the ingredients in ANNOVERA.
- take any Hepatitis C drug combination medicine containing
ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.
WARNINGS
ANNOVERA can cause serious side effects, including: blood
clots; toxic shock syndrome (TSS); liver problems, including liver
tumors; high blood pressure; gallbladder problems; changes in the
sugar and fat (cholesterol and triglycerides) levels in your blood;
headache; irregular or unusual vaginal bleeding and spotting
between your menstrual periods; depression; possible cancer in your
cervix; swelling of your skin especially around your mouth, eyes,
and in your throat (angioedema); dark patches of skin on your
forehead, cheeks, upper lip, and chin (chloasma). Call your
healthcare provider or get emergency medical care right away if any
of these serious side effects occur.
The most common side effects of ANNOVERA include:
- headache, including migraine
- nausea/vomiting
- vaginal yeast infection (candidiasis)
- lower/upper abdomen pain
- painful periods
- vaginal discharge
- urinary tract infection
- breast pain/tenderness
- irregular vaginal bleeding
- diarrhea
- genital itching
USE
ANNOVERA is a ring-shaped vaginal system with hormones used by
females to prevent pregnancy.
ANNOVERA has not been adequately studied in females with a body
mass index >29 kg/m2.
The risk information provided here is not complete. To learn
more, review the ANNOVERA Patient Information and talk with your
healthcare provider or pharmacist. The FDA-approved product
labeling, including Patient Information, can be found at
annovera.com/pi.pdf.
You may report side effects to the FDA at
www.fda.gov/medwatch or by calling 1-800-FDA-1088.
You may also report side effects to TherapeuticsMD at
1-888-228-0150.
About TherapeuticsMD
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the
unique changes and challenges women experience through the various
stages of their lives with a therapeutic focus in family planning,
reproductive health, and menopause management. The company is
committed to advancing the health of women and championing
awareness of their healthcare issues.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that the company intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as "believes," "hopes,"
"may," "anticipates," "should," "intends," "plans," "will,"
"expects," "estimates," "projects," "positioned," "strategy" and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the company’s filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, and include
the following: the effects of the COVID-19 pandemic; the company’s
ability to maintain or increase sales of its products; the
company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®,
and BIJUVA® and obtain additional financing necessary therefor;
whether the company will be able to comply with the covenants and
conditions under its term loan facility; whether the company will
be able to successfully divest its vitaCare business and the
proceeds that may be generated by such divestiture; the potential
of adverse side effects or other safety risks that could adversely
affect the commercialization of the company’s current or future
approved products or preclude the approval of the company’s future
drug candidates; whether the FDA will approve the efficacy
supplement for the lower dose of BIJUVA; the company’s ability to
protect its intellectual property, including with respect to the
Paragraph IV notice letters the company received regarding IMVEXXY
and BIJUVA; the length, cost and uncertain results of future
clinical trials; the company’s reliance on third parties to conduct
its manufacturing, research and development and clinical trials;
the ability of the company’s licensees to commercialize and
distribute the company’s products; the ability of the company’s
marketing contractors to market ANNOVERA; the availability of
reimbursement from government authorities and health insurance
companies for the company’s products; the impact of product
liability lawsuits; the influence of extensive and costly
government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases
and financial tables can be viewed and downloaded at its website:
www.therapeuticsmd.com/pressreleases.aspx.
___________________
1 Guttmacher Institute. Contraceptive Use in the United States.
Available at:
https://www.guttmacher.org/fact-sheet/contraceptive-use-united-states
2 Bearak J, et al. Global, regional, and subregional trends in
unintended pregnancy and its outcomes from 1990 to 2014: estimates
from a Bayesian hierarchical model. Lancet Global Health. April
2018;6(4): e380-e9. 3 Finer LB, et al. Declines in Unintended
Pregnancy in the United States, 2008–2011. New England Journal of
Medicine. March 2016;374(9 9):843-52). 4 Data on file. Survey
Report: Birth Control ATU. Ipsos Healthcare Team; May 12th,
2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201215005653/en/
Investor Contact Nichol Ochsner Vice President Investor
Relations 561-961-1900 Ext. 2088 nochsner@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024